Signifier Medical Technologies’ eXciteOSA®, the Only FDA-Authorized Daytime Therapy for Primary Snoring and Mild Obstructive Sleep Apnea, Demonstrates Real-World Adherence to Treatment of Over 80%
The results demonstrate that patients have used eXciteOSA therapy on over 80% of days during the first six weeks of treatment.
- The results demonstrate that patients have used eXciteOSA therapy on over 80% of days during the first six weeks of treatment.
- Sleep apnea is a serious condition, and adherence to treatment is both a challenge and a requirement.
- We understand patients desire for effective treatments that fit their lifestyle, said Dr. Jessie Bakker, Executive Vice President of Medical Affairs at Signifier.
- Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials.